Novo Nordisk Shares Dip on $490M Volume as Wegovy’s Cardiovascular Gains Clash with Generic Threats and Hiring Freeze

On September 4, 2025, Novo Nordisk (NVO) shares fell 1.06% with a trading volume of $490 million, ranking 206th in market activity. Recent developments highlight mixed signals for the stock. UBS reaffirmed a "Hold" rating, reflecting cautious optimism amid competitive pressures. Meanwhile, Wegovy demonstrated superior cardiovascular risk reduction compared to Eli Lilly’s Tirzepatide, reinforcing its market position. The drug also secured U.S. approval for MASH treatment and expansion into China, signaling strategic growth. Real-world data from Swiss trials further validated semaglutide’s efficacy in Type 2 diabetes patients.

However, challenges persist. Novo reportedly froze hiring as Wegovy faces increasing generic competition, particularly in China, where local manufacturers are preparing semaglutide alternatives. This could pressure long-term margins. Analysts note that while Novo maintains a strong product pipeline, its lead in the obesity drug market appears to narrow as Eli Lilly advances its own therapies. Regulatory and market dynamics remain critical to near-term performance.

Wegovy’s cardiovascular benefits and international expansion efforts currently offset concerns over hiring freezes and generic threats. The company’s ability to navigate these challenges will be pivotal in sustaining investor confidence.